NVO - Novo Nordisk Sets Timeframe For Its Next-Gen Experimental Obesity Drug | Benzinga
Novo Nordisk A/S’s (NYSE:NVO) head of development, Martin Holst Lange, expressed strong confidence in the drugmaker’s ability to launch the pill version of its experimental weight loss drug, amycretin, within this decade.
The optimism follows the announcement of robust early trial data.
The company said early trial data for its experimental obesity drug amycretin showed a higher weight loss than its Wegovy (semaglutide) treatment.
In the Phase 1 trial, oral amycretin showed that participants lost 13.1% of their weight after 12 weeks. That compares to a weight loss of 5.9% after 12 weeks in a trial for Wegovy.
Reuters notes that over 80% of participants remained on amycretin after the trial period, indicating a ...